Pen Needles Market to Reach USD 13.3 Billion by 2035 at 11.7% CAGR; USA Leads at 12.0%, France Trails at 10.8%

NEWARK, Del., October 1, 2026 - According to Future Market Insights (FMI), the global Pen Needles Market is projected to grow from USD 4.4 billion in 2025 to USD 13.3 billion by 2035, registering an 11.7% CAGR during the forecast period. Rising diabetes prevalence, increasing self-administration of injectable therapies, and advances in needle design are supporting demand for pen-based drug delivery systems.

Pen needles are becoming increasingly important in home-based diabetes management as patients seek convenient and less invasive methods for routine injections. FMI highlights improvements in needle thickness, length, comfort, safety features, and compatibility with insulin and other injectable therapies as factors influencing product adoption.

👉 Get Detailed Market Forecasts, Competitive Benchmarking, and Pricing Trends: https://www.futuremarketinsights.com/reports/sample/rep-gb-22419

Key Market Highlights

· Market Size (2025): USD 4.4 billion

· Forecast Value (2035): USD 13.3 billion

· CAGR (2025-2035): 11.7%

· Leading Product: Standard Pen Needles, with 87% share in 2025

· Leading Needle Length: 8mm, with 35% share in 2025

· Leading Therapy: Insulin, with 75% share in 2025

· Fastest-Growing Profiled Country: USA, at 12.0% CAGR

· Lowest CAGR Among Profiled Countries: France, at 10.8%

Global Segment Leaders

Standard Pen Needles - 87% Share: Standard pen needles account for the largest product share in 2025. Their broad compatibility with insulin pens, established clinical use, availability, and cost-effectiveness support continued demand, particularly in price-sensitive markets.

8mm Needles - 35% Share: The 8mm segment leads the needle-length category. FMI attributes its position to long-standing clinical use, broad patient compatibility, and established use for subcutaneous insulin administration.

Insulin Therapy - 75% Share: Insulin remains the dominant therapy segment as pen needles continue to serve patients requiring routine insulin administration, particularly those with type 1 diabetes and advanced type 2 diabetes.

Country-Level Performance

· United States - 12.0% CAGR (2025-2035): High diabetes prevalence, strong payer coverage, home injection, telehealth prescriptions, and integrated diabetes-care programs.

· Japan - 11.5% CAGR (2025-2035): Aging population, independent diabetes management, advanced needle technologies, and digital health integration.

· Germany - 11.3% CAGR (2025-2035): Statutory insurance coverage, structured diabetes education, and established healthcare infrastructure.

· United Kingdom - 11.0% CAGR (2025-2035): NHS preference for pen-based initiation, community diabetes support, and safety-focused needle adoption.

· France - 10.8% CAGR (2025-2035): Transition from vials to pens, preference for shorter needles, e-prescription integration, and public-clinic adoption.

The United States is projected to record the fastest growth among the five countries explicitly compared by FMI, at 12.0% CAGR through 2035. High diabetes prevalence and payer coverage support home injection, while device manufacturers are developing thinner cannulas, improved lubrication, and anti-coring features. Retail and telehealth channels are also expanding access to pen needles.

Japan follows at 11.5% CAGR, with demand linked to its aging population and the need to support independent diabetes management. FMI also highlights digital health integration and the development of advanced needle and injection technologies.

Germany is forecast to grow at 11.3%, supported by statutory insurance reimbursement, structured diabetes education, and established healthcare systems. The UK follows at 11.0%, with NHS directives favoring pen-based treatment initiation and continued emphasis on injection practices and safety.

France records the lowest CAGR among the five profiled countries at 10.8%. FMI associates growth with greater movement from vials to pens, demand for ultra-short needle formats, e-prescription integration, and evolving public-clinic practices.

Market Drivers, Restraints and Opportunities

The rising global prevalence of diabetes remains the central demand driver. As more patients require long-term injectable treatment, pen needles provide a practical route for self-administration outside traditional clinical settings. Patient education and greater familiarity with insulin pens are supporting adoption.

Technology development is also influencing the market. Manufacturers are working on thinner and shorter needles designed to improve comfort and reduce injection-related complications. Safety-enhanced products are gaining attention because they can help reduce needlestick injuries among healthcare workers and users.

The expansion of GLP-1 therapies creates an additional opportunity beyond traditional insulin delivery. FMI includes insulin, GLP-1, and growth hormone as the principal therapy categories in its market taxonomy, reflecting the broader use of pen-based injectable delivery.

Regional healthcare investment also creates opportunities. FMI identifies Asia Pacific as the fastest-growing region, supported by improving healthcare access, increasing diagnosis rates, and greater investment in diabetes care, particularly in India and China. Europe currently holds the leading regional position.

👉 Access the Complete Report in PDF Format:
https://www.futuremarketinsights.com/reports/brochure/rep-gb-22419

Competitive Landscape

The competitive landscape includes Becton, Dickinson and Company (BD), Novo Nordisk A/S, Ypsomed AG, Owen Mumford Ltd., HTL-STREFA S.A., Terumo Corporation, Allison Medical, Inc., Artsana S.p.A., Trividia Health, Inc., and Perrigo Company plc.

FMI identifies Novo Nordisk A/S as the leading company, with a 25% industry share. The company, along with BD and Terumo, benefits from broad product portfolios, established distribution networks, and participation across insulin, GLP-1, and growth-hormone delivery markets.

Ypsomed, Owen Mumford, and HTL-STREFA compete through specialized pen-needle solutions, while Allison Medical, Artsana, and other emerging participants target product innovation and cost-sensitive opportunities.

Recent Industry Developments

· June 2024: Novo Nordisk announced a USD 4.1 billion investment to construct a second fill-and-finish manufacturing facility in Clayton, North Carolina. The project is expected to add 1.4 million square feet of production space and 1,000 jobs.

· 2024: BD invested more than USD 10 million to expand manufacturing in the United States, including capacity additions at its Connecticut and Nebraska facilities. FMI says the expansion is intended to support supply reliability for needles and syringes, including pen needles.

Analyst Perspective

The accessible FMI report page identifies Sabyasachi Ghosh, Managing Director at Future Market Insights, in its analyst commentary:

"Pen needles are evolving alongside the broader shift toward self-administered injectable therapies, with product design increasingly focused on comfort, safety, and compatibility."

The report also emphasizes the growing importance of product innovation as manufacturers respond to changing patient preferences and the expansion of injectable therapies.

Report Scope

The Pen Needles Market is segmented by:

· Product: Standard Pen Needles, Safety Pen Needles

· Needle Length: 4mm, 5mm, 6mm, 8mm, 10mm, 12mm

· Therapy: Insulin, Glucagon-Like Peptide-1 (GLP-1), Growth Hormone

· Regions: North America, Western Europe, East Asia, South Asia

· Countries Covered: United States, Canada, United Kingdom, Germany, France, Italy, Spain, Netherlands, China, Japan, South Korea, India, Pakistan, Bangladesh, and other markets

· Historical Period: 2020-2024

· Forecast Period: 2025-2035

The report analyzes dollar sales, unit volumes, industry share, growth rates, regional demand, pricing strategies, customer preferences, regulatory conditions, competitive positioning, and innovation opportunities.

Access Full Report: https://www.futuremarketinsights.com/reports/pen-needles-market

About Future Market Insights

Future Market Insights (FMI) is a leading provider of market research and consulting services, offering syndicated and customized research across industries including healthcare, pharmaceuticals, and medical devices.

Related Reports:

· https://sites.google.com/view/healthcarewellnessinsights/semiconductor-based-ultrasound-imaging-market

· https://sites.google.com/view/healthcarewellnessinsights/relapsed-refractory-large-b-cell-lymphoma-treatment-market_1?read_current=1

· https://sites.google.com/view/healthcarewellnessinsights/behavioral-health-care-coordination-market_1?read_current=1

Rahul Singh
AVP - Marketing and Growth Strategy
Future Market Insights, Inc.
+91 8600020075
For Sales - sales@futuremarketinsights.com
For Media - Rahul.singh@futuremarketinsights.com
For Web - https://www.futuremarketinsights.com

Future Market Insights (FMI) is a global market intelligence and consulting firm providing comprehensive market research, competitive intelligence, and strategic business insights across industries. The firm delivers detailed forecasts, technology analysis, and data-driven recommendations that support informed decision-making for manufacturers, investors, distributors, and policymakers worldwide.

This release was published on openPR.